Discontinued — last reported Q3 '18

Products & Services · Maximum Potential Milestone Payment To Be Made

Sm04646 — Maximum Potential Milestone Payment To Be Made

Analysis

StatementSegment
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ3 2018
Last reportedQ3 2018

How to read this metric

An increase indicates higher contractual obligations tied to future success, while a decrease reflects the completion of milestones or the expiration of payment obligations.

Detailed definition

This metric represents the total aggregate value of contingent payments that the company is contractually obligated to p...

Peer comparison

Similar to contingent consideration or milestone obligations found in the R&D pipeline disclosures of other biotechnology and pharmaceutical companies.

Metric ID: uthr_segment_sm04646_maximum_potential_milestone_payment_to_be_made

Similar Metrics at Other Companies

Biogen logo
BiogenBIIBView metric
Insmed logo
InsmedINSMView metric
Biogen logo
BiogenBIIBView metric
Biogen logo
BiogenBIIBView metric
Biogen logo
BiogenBIIBView metric
Royalty Pharma logo
Royalty PharmaRPRXView metric

Frequently Asked Questions

What does sm04646 — maximum potential milestone payment to be made mean?
The total amount of future payments the company may owe to partners if specific development or sales goals are met for the SM04646 program.